Ibogaine and Federal Policy: What the Order Actually Does

This is the document behind almost every “ibogaine is being legalised” headline since April 2026, and most of the coverage describes something it does not say.

The document

Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness”, signed 18 April 2026 and published in the Federal Register on 22 April at 91 FR 21709.

A search of the Federal Register for presidential documents mentioning ibogaine returns exactly one result, and this is it. That is a fact anyone can reproduce in a minute, and it is worth doing before accepting any account of what the administration has done.

What it says about ibogaine

Twice, and both times inside a wider category.

The preamble states that psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy. It goes on to note that the FDA has granted Breakthrough Therapy designation to specific psychedelic drugs.

Section 2(b) directs the FDA and the Drug Enforcement Administration to facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act, including any necessary Schedule I handling authorisations for treating physicians and researchers.

Everywhere else, the order speaks of psychedelic drugs generally.

What it directs, section by section

The three limits that matter

It reschedules nothing. Ibogaine is Schedule I on the day the order was signed and Schedule I now. Where ibogaine is legal tracks the actual position, and why it is illegal covers how the classification was arrived at. An instruction to agencies to build a pathway is an instruction, not a pathway.

Section 5 cannot reach ibogaine yet. The rescheduling review it orders applies to products that have successfully completed Phase 3 clinical trials. No ibogaine product has. The trial that would have established a tolerated dose completed in January 2024 without reporting, and what has actually been run sets out the rest of the registry. The clause is real and it is waiting on evidence that does not exist.

Right to Try has conditions the order does not remove. The Act sets statutory eligibility requirements for both the patient and the drug. An executive order can direct agencies to build a pathway within that statute; it cannot rewrite it. We set out those conditions below. We could not establish that any ibogaine product currently meets them, and we are not going to assume it does.

What it does change

Three things, none of them legal status, and all of them real.

Money to the states. Section 3 sends at least $50 million through the Advanced Research Projects Agency for Health to states that have enacted or are developing programmes. That is a reallocation from existing funds rather than an appropriation, but it points federal money at exactly the state frameworks that Texas, Arizona and others have built.

The VA is now formally in the frame, and the memorandum exists. Section 4 directs HHS, the FDA and the Department of Veterans Affairs to collaborate on trial participation and data sharing, and to sign data-sharing memoranda. One has been signed. MOU 225-26-007 was approved for the FDA by Acting Commissioner Kyle Diamantas on 13 July 2026 and for the VA by Acting Under Secretary for Health John Figueroa, and it names the April 2026 order in its purpose clause. Its term is five years.

Read it and it deflates as you go. It says it “does not independently authorize the disclosure of any VA or FDA records or information” and that it “does not create binding, enforceable obligations against any Party”. It is a framework for collaboration between two agencies, not an access route for patients. The VA has published no policy of its own on ibogaine, and what access actually looks like for veterans covers the gap between that and the coverage.

Attention. Nature reported the order the day before it was published, noting that some researchers welcomed a streamlining of psychedelic investigation while warning that caution is needed, and describing ibogaine as tightly controlled and scientifically poorly understood. Search interest in the order rose to more than ten times its baseline in the month it appeared, and has fallen back since.

Where the FDA actually stands

The order is addressed to the FDA, so the sharpest test of what it did is what the agency has done since. Four findings, each from a federal source.

There is no approved ibogaine product, and this is checkable four ways. The Orange Book product file, downloaded whole, holds 48,664 records and contains the string “ibogaine” zero times. Drugs@FDA returns no match on ibogaine or noribogaine as an active ingredient, while the identical query for ketamine returns eleven applications, which is how you know the query works. DailyMed holds no label. The National Drug Code directory holds no entry.

Two of the order’s five sections are gated on a designation no ibogaine product is known to hold. Section 2(a) sends priority vouchers only to psychedelic drugs that “have received a Breakthrough Therapy designation”. Section 4 says the VA collaboration “shall prioritize drugs that have received a Breakthrough Therapy designation”. Whether any ibogaine product holds one cannot be established from outside, and that is deliberate. The FDA’s stated policy is that it “will not disclose information regarding sponsors who submitted requests for or who have been granted or denied breakthrough therapy designation”, because such requests sit inside a confidential investigational application. What can be established is what the agency did with the vouchers. Six days after the order it issued three, to two psilocybin programmes and one methylone programme. None went to ibogaine.

The one thing the FDA has allowed is for a different molecule. In the same announcement the agency said it was allowing an early phase clinical study of noribogaine hydrochloride to move forward, calling it “the first instance in which the FDA has allowed a clinical study in the U.S. of a derivative of ibogaine”, and adding that the decision “does not mean the drug has been approved or found to be safe or effective”. Noribogaine is ibogaine’s metabolite, not ibogaine, and the study is phase 1. Most headlines reported this as the FDA clearing an ibogaine trial.

The FDA has never published a Federal Register document mentioning ibogaine. Searching the Federal Register for the term returns 354 documents going back to 1994. Filtered to the FDA it returns zero. The 351 from the Justice Department are almost entirely routine DEA registration notices. Consistent with that, the agency’s finalised July 2026 guidance Psychedelic Drugs: Considerations for Clinical Investigations does not contain the string “iboga” anywhere. It defines its scope as classic psychedelics and entactogens, and leaves everything else to a trailing sentence saying the concepts “may also apply to other related products”.

What Right to Try actually requires

Section 2(b) directs the FDA and DEA to build a Right to Try pathway. The Act’s own conditions are what an executive order cannot touch.

A drug is eligible only if a phase 1 trial has been completed, it is not approved for any use, it is the subject of an active investigational application and of a trial intended to support approval, and its development is ongoing and not discontinued. A patient is eligible only if diagnosed with a life-threatening condition, having exhausted approved options and being unable to join a trial, certified by a physician who is not paid by the manufacturer.

Then the part that decides most cases. The FDA’s own page states that “the Right to Try Act does not require a sponsor to provide an eligible investigational drug to an eligible patient.” It is a permission for companies, not a right for patients. The agency adds that its role “is limited to receiving and posting” certain information and that it “does not review or approve requests”.

The pathway is also barely used. The FDA’s own paperwork burden estimate for Right to Try annual reporting assumes ten respondents filing ten reports a year, for the entire country and every drug.

The number nobody quotes

For 2026 the DEA set the aggregate production quota for ibogaine at 210 grams.

That is the whole quantity that may lawfully be manufactured in the United States this year, expressed as anhydrous base, across every registered manufacturer and every purpose. In the same notice the agency said it had matched the requests to registered manufacturers and concluded the quotas were “sufficient to support the legitimate research and scientific efforts toward an FDA-approved drug product”.

Set that beside a state programme with a nine-figure ambition and it tells you which constraint binds first.

What we could not establish

Whether the Right to Try pathway exists yet. The order directs the FDA and DEA to build one. We found no published rule, guidance or notice establishing it.

Whether any state has received Section 3 money. The order sets a floor of $50 million. We could not establish what has been allocated or to whom.

This page is a standing dossier rather than a news item, and it will be updated as those questions acquire answers rather than duplicated into new pages.